randomised clinical trials assessed the treatment-independent trends for overall colon cleansing quality versus overall colon lesion detection.

Methods Three multi-centre phase 3 clinical trials compared the cleansing efficacy and safety of the 1L PEG NER1006 (PLENVU®) versus standard bowel preparations in patients aged 18–85 years. Treatment-blinded assessment of colon cleansing quality was performed by both site colonoscopists (SC; who also detected all lesions per local practice) and by central readers (CR). Two validated cleansing scales were used: the Harefield Cleansing Scale (HCS) and the Boston Bowel Preparation Scale (BBPS; only by CR). Patients with documented HCS cleansing grades D-A, overall BBPS scores 0–9, and overall colon lesion counts were included in this analysis. Logistic regression trends were fitted to polyph (PDR) and adenoma (ADR) detection rates, using cleansing quality as a covariate.

Results Out of 1,985 randomised patients, 1,749 patients were included (table 1). With site colonoscopists’ HCS grades, the logistic regression for relative lesion detection demonstrated an odds ratio of 1.17, i.e., for each incremental increase in the HCS colon cleansing grade from D to A there was a 1.17 times increase in PDR (P=0.009) and ADR (P=0.019). With central readers, the corresponding increase was 1.24 times for PDR (P=0.005) and 1.26 times for ADR (P=0.006). With central readers, each incremental increase in the successful BBPS scores 6–9 resulted in a 1.08 times increase in PDR (P<0.001) and 1.10 times increase in ADR (P<0.001) versus failing BBPS scores 0–5.

Conclusions Adopting a better bowel preparation remains a good way to improve quality in colonoscopy. With both HCS and BBPS, an increased overall colon cleansing quality was associated with greater overall colon PDR and ADR across the full range from cleansing failures and up to high-quality cleansing.

| Abstract PTH-028 Table 1 Overall colon cleansing quality and relative lesion detection |
|--------------------|--------------------|--------------------|
| HCS Grade D-A assessed by site colonoscopists | HCS Grade D-A assessed by central readers | Overall BBPS Score 0–9 assessed by central readers |
| Patients, N | 1,749 | 1,749 | 1,749 |
| Relative lesion detection, odds ratio (95% CI); P-value |
| PDR | 1.17 (1.04–1.31); | 1.24 (1.07–1.43); | 1.08 (1.03–1.13); |
| 0.009 | 0.005 | <0.001 |
| ADR | 1.17 (1.03–1.33); | 1.26 (1.07–1.49); | 1.10 (1.05–1.15); |
| 0.019 | 0.006 | <0.001 |

**PTH-029 CLOSURE OF GASTROCUTANEOUS FISTULAS WITH AN OVER-THE-SCOPE-CLIP (OTSC) – A LARGE TERTIARY HOSPITAL EXPERIENCE**

Thomas Hollingworth*, Philip Boger, Emily Clarke, Praful Patel, Charlotte Rutter, Trevor Smith, Imdadur Rahman. University Hospital Southampton, Southampton, UK

Introduction Gastrocutaneous fistulae (GF) are a rare, but difficult to manage complication after percutaneous endoscopic gastrostomy (PEG) tube removal. In cases, refractory to conventional medical management various approaches have been used for their treatment including; surgical closure, through the scope clipping and endoscopic suturing with variable results. The over-the-scope-clip (OTSC) has an emerging role in the endoscopic closure of gastrointestinal wall defects, including persistent GF. The aim of this study was to assess the efficacy and safety of the use of OTSC for the closure of persistent GF.

Methods A prospectively kept database was analysed from September 2016 to January 2019 was undertaken of all persistent GF using an OTSC 12/6 GF clip. Prior to the deployment of an OTSC, the fistulous tract was disrupted using a wire brush, which also acted as a guide for placement. The use of ancillary techniques such as snare debulking or knife resection was utilised if needed. Primary outcome measures were; successful deployment of the OTSC, procedure time, complications and 30 day success. Secondary outcome measures were PEG dwell time prior to removal, time from diagnosis to closure and sedation type.

Results A total of 22 procedures were performed, on 12 male & 10 female patients with a mean age of 47. Median PEG dwell time was 16 months prior to removal. 64% of the procedures were performed with conscious sedation, with 36% requiring enhanced sedation with anaesthetic support. Technical success was 100%, with 2 procedures requiring ancillary techniques to facilitate the deployment of the OTSC, resulting in 1 complication of intra-procedural bleeding (stopped endoscopically). The median procedure time was 14 mins (range 9–35). A 30 & 90 day success was reported in 96% cases, with only one fistula recurring.

Discussion This is the largest cohort of patients with a persistent GF treated with an OTSC. This evolving procedure is an effective and safe method for the treatment of persistent GF. It has a much lower morbidity compared to surgery and shorter procedure times than more invasive endoscopic treatment options, such as endoscopic suturing.

**PTH-030 OUTCOMES OF HEMOSPRAY USE IN PEPTIC ULcer UPPER GASTROINTESTINAL BLEEDS: OUTCOMES FROM THE HEMOSPRAY REGISTRY**

1Mohamed Hussein*, 2Durayd Alzuabadi, 3Miguel Fraile, 4Jacobo Ortiz Fernandez-sordo, 5Krish Raghunath, 6Radu Rusu, 7John Dunn, 8Iohannes Rey, 9Shradhna Gulati, 9Bu’Hussain Hayee, 5Selena Dixon, 6Duncan Napier, 7John Anderson, 8Martin Dahan, 9Max Hu, 10Patricia Duarte, 11Phil Boger, 12John McGoran, 13Ynder Mainie, 14Alberto Muiruo, 15Sina Jamee-Dekxooie, 16Edward Despott, 17Cora Steihneber, 18Martin Goetz, 19Sharmila Subramaniam, 20Pradeep Bhandari, 11Laurence Lovat, 21Emmanuel Coron, 12Ralf Keislich, 13Rehan Haidy, 21UCIC, 21UCIC, 21UCIC, 21Nottingham Digestive Diseases Centre, UK; 2Guys and St Thomas Hospitals, UK; 3Kings college Hospital, UK; 4Bradford Teaching Hospital NHS Trust, UK; 5Gloucestershire Hospitals NHS Foundation Trust, UK; 6University Hospital of Nantes, France; 7University Hospital Southampton, UK; 8Belfast NHS Trust, UK; 9Royal Free Hospital, UK; 10Tbingen University Hospital, UK; 11University of Portsmouth, UK; 12Host Schindt Klinikum, Germany

Introduction Peptic ulcers are the commonest cause of upper Gastrointestinal bleeding (UGIB). Hemospray (Cook Medical, North Carolina, USA) is a novel haemostatic powder aimed to treat UGIB. The aim of this study is to look at outcomes in patients with peptic ulcer GI bleeds treated with hemospary in 13 centres.

Methods Data was prospectively collected on hemospray use in UGIBs in the UK, France and Germany (Jan’16-Sept’18). Hemospray was used for peptic ulcer UGIBs as a